Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/050852

International filing date: 28 February 2005 (28.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP
Number: 04100773.3
Filing date: 26 February 2004 (26.02.2004)

Date of receipt at the International Bureau: 13 April 2005 (13.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

PCT/EP2005/050852

28.02.05

Europäisches Patentamt | European Patent Office | Office européen des brevets

Bescheinigung | Certificate | Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. | Patent application No. | Demande de brevet n°

04100773.3

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

Anmeldung Nr:
Application no.: 04100773.3
Demande no:

Anmeldetag:
Date of filing: 26.02.04
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Applied Research Systems ARS Holding N.V.
Pietermaai 15
Curacao
ANTILLES NEERLANDAISES

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Method for preparing pyrrolidine oximes

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s) revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07D413/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR LI

Method for preparing pyrrolidine oximes

Summary of the invention

The present invention is related to a new synthesis for preparing pyrrolidine oximes of general formula (I). The compounds are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea.

Field of the invention

The present invention is related to a new synthesis for preparing pyrrolidine oximes of general formula (I) :



(I)

A is a carbonyl group -(C=O)-.

B is either an amido group of formula –(C=O)-NR_3R_4 or a substituted or unsubstituted oxadiazole ring.

R_1 is H or an unsubstituted or substituted C_1-C_6-alkyl. Preferably, R_1 is a methyl group.

R_2 is selected from the group comprising or consisting of unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted saturated or unsaturated 3-8-membered cycloalkyl. More a preferred is an aryl, in particular a phenyl group which is optionally substituted, e.g. by a further phenyl group (thus providing a biphenyl moiety).

R_3 and R_4 are independently selected from the group comprising or consisting of hydrogen, unsubstituted or substituted C_1-C_6 alkyl, unsubstituted or substituted C_2-C_6

alkenyl, unsubstituted or substituted C_2-C_6 alkynyl, unsubstituted or substituted alkoxy, unsubstituted or substituted sulfanyl, acyl, alkoxycarbonyl, aminocarbonyl, unsubstituted or substituted saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted C_1-C_6-alkyl aryl, unsubstituted or substituted C_1-C_6-alkyl heteroaryl.

Preferred pyrrolidine derivatives are those compounds according to formula I wherein R_1 is a methyl group, R_2 is a substituted or unsubstituted biphenyl.

According to one specific embodiment B is an amido group of the formula –(C=O)NHR$_5$, wherein R_5 is an unsubstituted or substituted C_1-C_6-alkyl aryl group, e.g. a phenylethyl group which is optionally substituted with hydrophilic moieties including amino or hydroxy.

According to a further specific embodiment, the substituent B is a 1,2,4-oxadiazole substituent which may be attached to the pyrrolidine ring according to the following modes (Xa) or (Xb):



(Xa)

(Xb)

In said formulae (Xa) and (Xb), R_7 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, unsubstituted or substituted C_1-C_6-alkyl, unsubstituted or substituted C_2-C_6-alkenyl, unsubstituted or substituted C_2-C_6-alkynyl, wherein said alkyl, alkenyl, alkynyl chains may be interrupted by a heteroatom selected from N, O or S, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted saturated or unsaturated 3-8-membered cycloalkyl, unsubstituted or substituted heterocycloalkyl, wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl, heterocycloalkyl, aryl or heteroaryl group, an acyl moiety, unsubstituted or substituted C_1-C_6-alkyl aryl, unsubstituted or substituted C_1-C_6-alkyl heteroaryl, unsubstituted or

substituted C_1-C_6-alkenyl aryl, unsubstituted or substituted C_1-C_6-alkenyl heteroaryl, unsubstituted or substituted C_1-C_6-alkynyl aryl, unsubstituted or substituted C_1-C_6-alkynyl heteroaryl, unsubstituted or substituted C_1-C_6-alkyl cycloalkyl, unsubstituted or substituted C_1-C_6-alkyl heterocycloalkyl, unsubstituted or substituted C_1-C_6-alkenyl cycloalkyl, unsubstituted or substituted C_1-C_6-alkenyl heterocycloalkyl, unsubstituted or substituted C_1-C_6-alkynyl cycloalkyl, unsubstituted or substituted C_1-C_6-alkynyl heterocycloalkyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted aminocarbonyl , substituted or unsubstituted C_1-C_6-alkyl carboxy, substituted or unsubstituted C_1-C_6-alkyl acyl, unsubstituted or substituted C_1-C_6-alkyl acyloxy, unsubstituted or substituted C_1-C_6-alkyl alkoxy, unsubstituted or substituted C_1-C_6-alkyl alkoxycarbonyl, unsubstituted or substituted C_1-C_6-alkyl aminocarbonyl, unsubstituted or substituted C_1-C_6-alkyl acylamino, unsubstituted or substituted C_1-C_6-alkyl ureido, unsubstituted or substituted C_1-C_6-alkyl amino, unsubstituted or substituted C_1-C_6-alkyl ammonium, unsubstituted or substituted C_1-C_6-alkyl sulfonyloxy, unsubstituted or substituted C_1-C_6-alkyl sulfonyl, unsubstituted or substituted C_1-C_6-alkyl sulfinyl, unsubstituted or substituted C_1-C_6-alkyl sulfanyl, unsubstituted or substituted C_1-C_6-alkyl sulfonylamino, unsubstituted or substituted C_1-C_6-alkyl aminosulfonyl, hydroxy, halogen, cyano.

In a specific embodiment R_7 is an unsubstituted or substituted C_1-C_6-alkyl group, e.g. a methyl or an ethyl group which may optionally be substituted with hydrophilic moieties including amino or hydroxy, or R_7 is a 3 to 8 membered cycloalkyl optionally containing one or 2 heteroatoms, e.g. a pyrrolidine, furanyl, thienyl, piperidine, morpholine or piperazine.

The method employs commercially available, or easily obtainable, starting compounds.

Background of the invention

The synthetic approach for preparing pyrrolidine oximes of formula (I) is well known. Several documents disclose the synthesis of such compounds.

WO 01/72705 for instance discloses the synthesis for the amide derivative of pyrrolidine oxime shown below (Scheme 1).

SCHEME 1



PG is a protecting group. A typical starting compound used in WO 01/72705 is Boc-protected pyrrolidine derivative (e.g. 1-(*tert*-butoxycarbonyl)-4-hydroxy-2-pyrrolidinecarboxylic acid or its follow-up product 1-(*tert*-butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid; cf. synthesis of intermediate 7).

A further application related to pyrrolidine oximes is WO 02/102799. The patent application relates to the use of a protected pyrrolidine derivative as starting compound and describes the following specific pathway for synthesizing oxadiazole pyrrolidine oximes (see Scheme 2).

SCHEME 2



PG is a suitable protecting group. Again, the starting compound is a Boc-protected pyrrolidine (e.g. 1-(*tert*-butoxycarbonyl)-4-oxo-2-pyrrolidinecarboxylic acid).

Still a further application is WO 99/52868 (Procter & Gamble) disclosing the synthesis of hydroxamide derivatives of pyrrolidine oxime. This pathway does not involve a protected starting compound (see scheme 3), but provides structurally different end-products (hydroxamides).

SCHEME 3



The present invention provides a new method for synthesizing pyrrolidine oxime of formula (I) that does not require the use of a Boc-protected pyrrolidine.

Description of the invention

The present invention allows to overcome the above said problems by a synthesis that involves four steps and moreover uses, as starting compounds, compounds that can be easily synthesized or are commercially available.

The following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly through-out the specification and claims unless an otherwise expressly set out definition provides a broader definition.

"C_1-C_6 -alkyl" refers to monovalent alkyl groups having 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *tert*-butyl, n-hexyl and the like.

"Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (*e.g.*, phenyl) or multiple condensed rings (*e.g.*, naphthyl). Preferred aryl include phenyl, naphthyl, phenantrenyl and the like.

"Heteroaryl" refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatic groups include optionally substituted pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadia-zolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, phthalazinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, phteridinyl, carbazolyl, xanthenyl or benzoquinolyl.

"C_3-C_8-cycloalkyl" refers to a saturated carbocyclic group of from 3 to 8 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl). Preferred cycloalkyl include cyclopentyl, cyclohexyl, norbornyl and the like.

"Amino" refers to the group –NRR' where each R, R' is independently hydrogen, "C_1-C_6-alkyl", "C_2-C_6-alkenyl", "C_2-C_6-alkynyl", "C_3-C_8-cycloalkyl", "heterocyclo-alkyl", "aryl", "heteroaryl", "C_1-C_6-alkyl aryl" or "C_1-C_6-alkyl heteroaryl", "C_2-C_6-alkenyl aryl", "C_2-C_6-alkenyl heteroaryl", "C_2-C_6-alkynyl aryl", "C_2-C_6-alkynyl-heteroaryl", "C_1-C_6-alkyl cycloalkyl", "C_1-C_6-alkyl heterocycloalkyl", and where R and R', together with the nitrogen atom to which they are attached, can optionally form a 3-8-membered heterocycloalkyl ring.

"Substituted or unsubstituted" : Unless otherwise constrained by the definition of the individual substituent, the above set out groups, like "alkyl", "aryl" and "heteroaryl" etc. groups can optionally be substituted with from 1 to 5 substituents selected from the group consisting of "C_1-C_6-alkyl", "amino", "aryl", "heteroaryl", "sulfinyl", "sulfonyl", "alkoxy", "sulfanyl", "halogen", "carboxy", cyano, hydroxy, mercapto, nitro, and the like.

The method, according to the present invention, comprises the following 4 steps:

In accordance with the present invention, the compounds of formula (I) are prepared starting from an unprotected 4-hydroxypyrrolidinecarboxylic acid of formula (II). The compound (II) is commercially available or may be prepared according to known techniques.

Step 1 : In a first step (cf. Scheme 4), the pyrrolidine of formula (II) is transformed into an acyl derivative of formula (IV) using a suitable acylating agent (III), e.g. an acyl chloride, an anhydride, a carboxylic acid or an ester. A preferred acylating agent is 1,1'-biphenyl-4-carbonyl chloride or 2'-methyl-1,1'-biphenyl-4-carbonyl chloride. The preparation of such compound is disclosed for instance in WO 01/72705.

SCHEME 4



(II) (IV)

Preferably the reaction is performed in presence of a base e.g. sodium hydroxide or potassium hydroxide (Schotten-Baumann conditions) or using an organic base including triethylamine, N,N-diisopropylethylamine or pyridine.

Step 2 : The acyl derivative (IV) is then oxidized, with a suitable oxidizing agent, obtaining a pyrrolidone of formula (V). One suitable oxidizing agent is the pyridine-sulfurtrioxide complex (Py-SO_3) using DMSO as solvent. Preferably, the reaction is performed in presence of triethylamine.

Additional examples for suitable oxidizing reagents include e.g. oxalyl chloride/ DMSO, trifluoroacetic acid anhydride/DMSO, dicyclohexyl carbodiimide/DMSO, pyridinium dichromate, pyridinium chlorochromate, Jone's oxidation or the Dess-Martin periodinane 1,1,1-tris(acetyloxy)-1-λ^5, 2-benziodoxol-3(1H)-one.

SCHEME 5

(IV) (V)

Step 3 : Then the compound of formula (V) is transformed into compound (VII) using a suitable alkoxylamine, aryloxylamine or hydroxylamine of general formula (VI), e.g. O-methylhydroxylamine hydrochloride(such compound is commercially available) in the presence of an organic base, such as triethylamine or N,N-diisopropylethylamine..

SCHEME 6



(V) (VI) (VII)

Step 4 : The compound (VII) is then transformed into either of the compounds (Ia) or (Ib) using either an amine of general formula (VIII) or an N-hydroxyamidoxime of general formula (IX). The preparation of N-hydroxyamidoxime of general formula (IX) is disclosed for instance in WO 02/102799.

SCHEME 7



In the case that the final product (Ic) is to be generated, Step 4 has to be adjusted in the sense that first a N-hydroxyamidoxime) (VIIb) is to be provided by transforming compound (VII) into a nitrile (VIIa) (e.g. directly form the acid (this is known in the literature) or via an amide) which is then further reacted with a carboxylic acid of formula R^7-COOH or e.g. the corresponding acyl chloride to finally yield compound (Ic) after heating of the intermediate product e.g. with an excess of pyridine. Preferably, coupling agents are used for the reaction of amidoxime (VIIb) with the carboxylic acid, e.g. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, carbonyldiimidazole, dicyclohexylcarbodiimide, pivaloyl chloride, isobutyl chloroformate (or any other of the usual reagents known for peptide bond formation).

The final products of formulae (Ia), (Ib), (Ic) may be further transformed, in particular in respect to the moiety R^1, R^2, R^7. Thus, a final product (Ic) wherein R^7 contains a functional group, said moiety may be transformed to another moiety by suitable means, including hydrolysis, esterification, saponification, alkylation etc.. Also, the compounds of the invention may be subjected to further purification steps, including chromatography and re-crystallization.

The new synthetic approach for preparing the compound of formula (I) does not involve the use of the relatively expensive Boc-protected pyrrolidine but from cheap and cheap and easily available 3-hydroxyproline.

A further advantage of the new synthetic approach concerns the preparation of compounds having polar moieties attached to the 2-carboxamide or the 2-oxadiazole position (for instance R^3, R^4, R^7 being a moiety (e.g. an alkyl or aryl) that contains e.g. a hydroxy or amino substituent, including a cyclic amine). The present new method avoids a final N-capping step (as seen in Scheme 2), implying the use of a nucleophile (e.g. acyl chloride) that may choose between the pyrrolidine amine and said second polar moiety, e.g. a hydroxy or amino substituent, to react.

In one embodiment, the new synthetic approach for preparing may be employed for the industrial manufacturing of the compounds of formula (I).

The present invention shall be illustrated by means of the following examples.

Example 1 : Preparation of (2*S*,4*E* and 4*Z*)-*N*-[(2*S*)-2-hydroxy-2-phenylethyl]-4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidine carboxamide

Step 1 : Preparation of (4*R*)-4-hydroxy-1-[(2'-methyl-1,1'-biphenyl-4-yl)-carbonyl]-*L*-proline (compound (IV) in scheme 4)

4-Hydroxy-*L*-proline (0.625wt) and water (3.3vol) are charged to a 20L flange flask. Triethylamine (2.42vol) was added to the contents dropwise such that the temperature is maintained in the range 10 to 20°C. Tetrahydrofuran (5.0vol) was added and the reaction mixture was cooled to 0 to 5°C. 2'-methyl-1,1'-biphenyl-4-carboxylic acid chloride, 1.0wt) and tetrahydrofuran (5.0vol) were charged to a separate flask, stirred for 5 to 10 minutes and then added to the reaction mixture ensuring that the temperature was maintained in the range 0 to 10°C. The reaction mixture was warmed to 15 to 25°C over 60-120 minutes and maintained at 15 to 25°C until reaction completion was noted by TLC analysis. The resultant is concentrated under vacuum at 35 to 40°C, water (10.0vol) and ethyl acetate (5.0vol) are added to the residue and the contents stirred for 5 to 10 minutes. The layers were separated, the

aqueous phase acidified to pH1 with aqueous hydrochloric acid (6M, approx. 3.0vol) and the resulting slurry cooled to and aged at 0 to 10°C for 25 to 40 minutes. The precipitate was collected by filtration, the isolated solid transferred to a suitable flange flask and slurried in warm (35 to 60°C) water (5.0vol) for 10 to 25 minutes. The solid was collected by filtration and the hot water slurry treatment was repeated as above. After the second slurry treatment the solid was azeotropically dried with toluene (2x 5.0vol) at 40 to 50°C. Ethyl acetate (2.5vol) and heptanes (2.5vol) were added to the residue, the resulting slurry cooled to and aged 0 to 5°C for 30 to 40 minutes, filtered, the collected solids washed with pre-cooled (0 to 5°C) ethyl acetate:heptanes (1:1, 2.0vol) and dried under vacuum at 30 to 40°C to constant weight to give (4*R*)-4-hydroxy-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]-*L*-proline as a white solid. Yield: 85.9%.

Step 2: Preparation of 1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]-4-oxo-*L*-proline (compound (V) in scheme 5)

(4*R*)-4-Hydroxy-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]-*L*-proline (product of Step 1, 1.0wt) and dimethyl sulphoxide (2.5vol) were charged to a 20L flange flask. The contents were heated to 35 to 40°C and maintained at this temperature until complete dissolution was achieved. The solution was cooled to 5 to 10°C under a nitrogen atmosphere and triethylamine (3.0vol) was added such that the temperature was maintained in the range 5 to 20°C. Pyridine-sulphur trioxide complex (1.47wt) and dimethyl sulphoxide (4.9vol) were charged to a separate flask, stirred for 5 to 10 minutes and then added to the reaction mixture such that the temperature was maintained in the range 15 to 25°C. The reaction was stirred at 15 to 25°C until reaction completion is noted by HPLC analysis (typically 1 to 3 hours). The vessel contents were cooled to 0 to 10°C and quenched with aq. hydrochloric acid (3M, 8vol) maintaining the temperature below 30°C. Tetrahydrofuran (5.0vol) and heptanes (1.0vol) were then added, the layers separated, the aqueous phase extracted with tetrahydrofuran (2x 5.0vol) and the combined organics washed with aq. hydrochloric acid (1M, 2x 2.0vol) and saturated brine solution (2x 2.0vol). The aqueous washes were combined and back-extracted with tetrahydrofuran (2x 1.0vol), the organics combined, dried over magnesium sulphate (3wt) and filtered. The filter-

cake was washed with tetrahydrofuran (1.0vol) and the filtrates are concentrated under vacuum at 40 to 45°C to give a pale brown foam. Ethyl acetate (10.0vol) was added to the residue, the contents stirred for 5 to 10 minutes and the solvent removed under vacuum at 40 to 45°C. The residue was transferred to a flask, ethyl acetate (8.0vol) was added and the contents were heated to reflux. A slurry of activated carbon (0.14wt) in ethyl acetate (5.0vol) was added and reflux conditions re-established and maintained for 20 to 30 minutes. The contents were cooled to 40 to 45°C, filtered, the filter-cake was washed with ethyl acetate (2.5vol) and the filtrates concentrated to 2.5 to 3.0vol under vacuum at 40 to 45°C. The slurry was diluted with ethyl acetate (0.5vol) and heated to reflux. Heptane (3.0vol) was added and the contents allowed to cool to 15 to 25°C over 1 to 2 hours. The slurry was further cooled to at 0 to 5°C for 2 to 3 hours, filtered and the filter-cake washed with ethyl acetate:heptane [(1:1), 1.0vol] pre-cooled to 0 to 5°C followed by heptane (5.0vol). The isolated solid was dried under vacuum at 40 to 45°C to give 1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]-4-oxo-*L*-proline as an off-white solid. Yield: 60.3%.

Step 3: Preparation of 4-methoxyimino-1-[(2'-methyl-1,1'-biphenyl-4-yl)-carbonyl]-*L*-proline (compound (VII) in scheme 6)

1-[(2'-Methyl-1,1'-biphenyl-4-yl)carbonyl]-4-oxo-*L*-proline (of Step 2, 1.0wt), *O*-methyl-hydroxylamine hydrochloride (0.285wt) and dichloromethane (20vol) were charged to a 20L flange flask and cooled to 0 to 5°C. Triethylamine (0.91vol) was charged to the flask such that the temperature was maintained in the range 0 to 10°C, the reaction mixture was warmed to 15 to 25°C and maintained within this temperature range for 16 to 20 hours. The reaction mixture was concentrated under vacuum at 40 to 45°C, the residue dissolved in ethyl acetate (10.0vol) and washed with aq. hydrochloric acid (1M, 2x 5.0vol). The aqueous washes were combined and back extracted with ethyl acetate (5.0vol), the organic extracts combined and washed with satuarted brine solution (10.0vol), dried over magnesium sulphate (0.5wt), filtered and the filter-cake washed with ethyl acetate (5.0vol). The filtrates were concentrated under vacuum at 40 to 45°C to give 4-methoxyimino-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]-*L*-proline in the expected *E*:*Z* mixture. Yield: 95.6%.

Step 4 : Preparation of N-[2-hydroxy-2-phenylethyl]4-(methoxyimino)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidine carboxamide (compound (Ia) in scheme 7)

4-Methoxyimino-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]-*L*-proline (of Step 3, 1.0wt) and dichloromethane (10.0vol) were charged to a 20L flange flask and cooled to 0 to 5°C under an atmosphere of nitrogen. *N*-Methylmorpholine (0.78vol) was added at 0 to 5°C followed by pivaloyl chloride (0.37vol) at 0 to 5°C. The vessel contents were stirred at 0 to 5°C until the formation of the mixed anhydride was complete (typically 30 to 60 minutes). To a separate 20L flange flask is charged (*S*)-2-amino-1-phenylethanol (0.47wt, 1.2eq.) and dichloromethane (3.0vol) and the resultant was stirred for 5 to 25 minutes. The solution was then cooled to 10 to 15°C and was charged with the mixed anhydride such that the temperature was maintained at 5 to 15°C. The reaction mixture was warmed to 15 to 25°C and maintained within this temperature range until reaction completion is noted by HPLC analysis. The resultant was concentrated under vacuum at 35 to 45°C, the residue partitioned between *tert*-butyl methyl ether (TBME, 10.0vol) and aq. citric acid solution (0.1M, 5.0vol), the layers separated and the organic phase further was washed with aq. citric acid solution (0.1M, 2x 5.0vol), sat. aq. sodium hydrogen carbonate solution (2x 5.0vol) and sat. brine solution (5.0vol). The organic phase was dried over magnesium sulphate (1wt), filtered and the filter-cake was washed with TBME (2.0vol). The filtrates were concentrated under vacuum at 35 to 45°C to give a brown semi-solid. Dichloromethane (5.0vol) was added to the residue and the contents were concentrated under vacuum at 35 to 45°C to a gum. The process was repeated with a further portion of dichloromethane (1.0vol) and a crude end product was obtained as the expected *E*:*Z* mixture. Yield: 84.4%

Example 2: (3*E*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone *O*-methyloxime; (3*Z*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]-3-pyrrolidinone *O*-methyloxime

Step 1: Preparation of (2*S*,4*R*)-1-(biphenyl-4-ylcarbonyl)-4-hydroxy-pyrrolidine-2-carboxylic acid (compound (IV) in scheme 4)

4-Hydroxy-*L*-proline (0.670Kg, 5.11mol, 0.67wt), tetrahydrofuran (5.00L, 5.0vol) and water (3.30L, 3.3vol) were charged to a 20L flange flask. Triethylamine (2.570L, 2.57vol) was added dropwise such that the temperature was maintained in the range 10 to 15°C and the resultant cooled to 0 to 5°C. 1,1'-Biphenyl-4-carbonyl chloride (1.00Kg, 3.78mol, 1.0wt) and tetrahydrofuran (5.00L, 5.0vol) were charged to a separate flask, stirred as a slurry for 5 to 10 minutes and added to the reaction mixture over 40 to 50 minutes ensuring that the temperature was maintained in the range of 0 to 10°C. The reaction mixture was heated to 15 to 25°C over 60 to 120 minutes and maintained at 15 to 25°C until reaction completion was noted by TLC analysis (dichloromethane:methanol:acetic acid 90:10:1; visualisation UV; product R_f 0.13). The reaction mixture was concentrated under reduced pressure at 35 to 40°C, water (8.00L, 8.0vol) and ethyl acetate (5.00L, 5.0vol) added to the residue and the contents stirred for 5 to 10 minutes. The layers were separated, the aqueous phase acidified to pH1 with rapid addition of aqueous hydrochloric acid (6M, approx. 900mL, 0.9vol) and the resulting slurry cooled to 0 to 10°C for 40 to 50 minutes. The precipitate was collected by filtration, the isolated solids slurried in warm water (35 to 60°C, 5.00L, 5.0vol) for 10 to 25 minutes and the solids collected by filtration. The warm water slurry treatment was repeated as above. The collected solids were combined with those from an equally sized batch, charged to a 20L flange flask, acetone (10.00L, 5.0vol) added and the reaction mixture heated to and maintained at reflux (approx. 65°C) for 10 to 20 minutes. The resultant was allowed to cool to 15 to 25°C, stirred at 15 to 25°C for 12 to 18 hours and further cooled to and aged at 0 to 5°C for 60 minutes. The precipitate was collected by filtration and washed with ethyl acetate:acetone (1:1, 4.00L, 2vol). The solids were pulled dry on the filter and further dried under vacuum at 40 to 45°C to constant weight to give (2*S*,4*R*)-1-(biphenyl-4-ylcarbonyl)-4-hydroxy-pyrrolidine-2-carboxylic acid as a beige solid. The filtrates were concentrated to approximately 3.00L under reduced pressure to afford a second crop of material which was collected by filtration, washed with ethyl acetate:heptanes (1:1, 2x 4.00L, 2x 2vol) and pulled dry on the filter. Drying under vacuum at 40 to

45°C to a constant weight gave the title compound as a beige solid. Total output: 2.616Kg, Yield : 91.9%).

Step 2: Preparation of (2*S*)-1-(biphenyl-4-ylcarbonyl)-4-oxo-pyrrolidine-2-carboxylic acid (compound (V) in scheme 5)

(2*S*,4*R*)-1-(Biphenyl-4-ylcarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (0.806Kg, 1.0wt) and dimethyl sulfoxide (5.00L, 6.25vol) were charged to a 20L flange flask and stirred under nitrogen until complete dissolution was achieved. The solution was cooled to 10 to 15°C and triethylamine (2.40L, 3.0vol) was added such that the internal temperature was maintained in the range 10 to 20°C. Pyridine-sulfur trioxide complex (1.224Kg, 1.53wt) was charged to the reaction mixture portion-wise such that the internal temperature was maintained in the range 10 to 25°C. Stirring at 15 to 25°C was continued until reaction completion was noted by TLC analysis (dichloromethane:methanol:acetic acid 90:10:1; product R_f 0.28), typically within 1 to 3h. The reaction mixture was cooled to 0 to 10°C and quenched with aq. hydrochloric acid (3M, 6.460L, 8.0vol) maintaining the temperature below 30°C. Tetrahydrofuran (2.00L, 2.5vol) and ethyl acetate (2.00L, 2.5vol) were added, the layers separated, the aqueous phase extracted with tetrahydrofuran:ethyl acetate (1:1, 4.00L, 5.0vol) and the combined extracts washed with aq. hydrochloric acid (1M, 2x 1.60L, 2x 2.0vol) and sat. brine solution (1.60L, 2.0vol). Activated carbon (160g, 0.2wt) was charged to the organic phase and the resulting slurry heated to and maintained at reflux (65 to 70°C) for 0.5h. The reaction mixture was cooled to 20 to 30°C, magnesium sulphate (375g, 0.5wt) charged, stirring maintained for 10 minutes the mixture filtered through celite. The collected solids were washed with ethyl acetate (2x 0.800L, 2x 1.0vol) and the combined filtrates concentrated under reduced pressure at 40 to 45°C to give the title compound (2*S*)-1-(biphenyl-4-ylcarbonyl)-4-oxo-pyrrolidine-2-carboxylic acid as a viscous, orange oil (0.769Kg, Yield : 96.0%). The material was used in the next step without further purification.

Step 3: Preparation of (2*S*)-1-(biphenyl-4-ylcarbonyl)-4-(methoxyimino)-pyrrolidine-2-carboxylic acid (compound (VII) in scheme 6)

Crude (2*S*)-1-(biphenyl-4-ylcarbonyl)-4-oxopyrrolidine-2-carboxylic acid (1.550Kg, 5.01mol, 1.0wt), *O*-methylhydroxylamine hydrochloride (0.620Kg, 7.42mol, 0.40wt) and dichloromethane (12.40L, 8.0vol) were charged to a 20L flange flask and cooled to 0 to 5°C. Triethylamine (1.752L, 1.13vol) was added to the reaction mixture over 45 to 60 minutes such that the internal temperature was maintained in the range 0 to 10°C. The reaction mixture was warmed to 15 to 25°C and maintained in this temperature range until reaction completion (typically 12 to 18 hours) was noted by TLC analysis (dichloromethane:methanol:acetic acid 90:10:1, visualisation UV; product R_f 0.27, 0.35 *Z*, *E*). The reaction mixture was concentrated under reduced pressure at 40 to 45°C, the residue dissolved in ethyl acetate (12.40L, 8.0vol) and washed with aq. hydrochloric acid (2M, 2x 4.650L, 2x 3.0vol). The aqueous washes were combined and back extracted with ethyl acetate (4.650L, 3.0vol). The organic extracts were combined, washed with sat. brine solution (4.650L, 3.0vol), dried over magnesium sulphate (770g, 0.5wt), filtered and the filter-cake washed with ethyl acetate (4.650L, 3.0vol). The filtrates were concentrated under reduced pressure at 40 to 45°C to give a beige solid. The crude product was slurried in ethyl acetate (3.10L, 2.0vol) at 15 to 20°C, cyclohexane (12.40L, 8.0vol) added over 15 minutes and the resulting slurry cooled to and aged at 0 to 5°C for 1h. The precipitate was collected by filtration, washed with ethyl acetate:cyclohexane (1:2; 4.650L, 3.0vol) and dried under vacuum at 40 to 45°C to constant weight to afford the title product as a beige solid (1.132Kg, Yield : 66.8%).

The isolation filtrates (from 9 runs of the above reaction) were combined and concentrated under reduced pressure at 40 to 45°C. The residue (approximately 1.00Kg) was hot slurried (70 to 75°C) in ethyl acetate (7.00L), cooled to and aged at 0 to 5°C for 2 hours, filtered and the collected solids dried under vacuum at 40 to 45°C to constant weight to provide a second crop of (2*S*)-1-(biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidine-2-carboxylic acid (0.732Kg, 4.9%th).

Step 4a: Preparation of (2*S*)-1-(biphenyl-4-carbonyl)-5-[3-(2-triethylsilanyl-oxyethyl)-1,2,4-oxadiazol-5-yl]-pyrrolidin-3-one-*O*-methyloxime (compound (Ib) in scheme 7)

(2*S*)-1-(Biphenyl-4-ylcarbonyl)-4-(methoxyimino)pyrrolidine-2-carboxylic acid (0.560Kg, 1.0wt) and tetrahydrofuran (8.40L, 15.0vol) were charged to a 20L flange flask and cooled to 0 to 5°C. Carbonyl diimidazole (0.280Kg, 0.5wt) was added portion-wise such that the internal temperature was maintained in the range 0 to 10°C. The reaction mixture was warmed to and stirred at 15 to 20°C until reaction completion (1 to 2h) was noted by TLC analysis (ethyl acetate, visualisation UV). *N*-Hydroxy-3-triethylsilanyl-oxypropionamidine (0.381Kg, 0.68wt, 1.0eq. corrected for silanol content) as a solution in tetrahydrofuran (2.80L, 5.0vol) was then added in one portion and stirring continued at 15 to 25°C with reaction monitoring by TLC analysis (ethyl acetate, visualisation UV). Reaction completion was noted after 1 hour. The reaction mixture was concentrated under reduced pressure at 40 to 45°C and the residue combined with two batches of similar input. Pyridine (5.040L, 3vol) was added to the combined material and the resultant heated to and maintained at 85 to 90°C until HPLC analysis indicated complete cyclisation. The reaction mixture was concentrated under reduced pressure at 40 to 45°C, the dark oily residue treated with ethyl acetate (16.80L, 10vol) and washed with 25% aq. citric acid solution (3x 5.00L, 3x 3.0vol). The aqueous extracts were combined and back-extracted with ethyl acetate (5.00L, 3vol), the combined organics washed with brine (5.00L, 3.0vol), dried over magnesium sulphate (1.680Kg, 1wt), filtered and the filter-cake washed with ethyl acetate (1.70L). The combined filtrates were concentrated under reduced pressure at 40 to 45°C to yield crude (2*S*)-1-(biphenyl-4-carbonyl)-5-[3-(2-triethylsilanyloxyethyl)-1,2,4-oxadiazol-5-yl]pyrrolidin-3-one-*O*-methyloxime as a brown oil which was used without further purification (2.796Kg, 108%).

Step 4b: Preparation of (2*S*)-1-(biphenyl-4-carbonyl)-5-[3-(2-hydroxyethyl)-1,2,4-oxadiazol-5-yl]pyrrolidin-3-one-*O*-methyloxime

Crude (2*S*)-1-(biphenyl-4-carbonyl)-5-[3-(2-triethylsilanyloxyethyl)-1,2,4-oxadiazol-5-yl]-pyrrolidin-3-one-*O*-methyloxime (1.398Kg, 1.0wt) as a solution in tetrahydrofuran (6.990L, 5.0vol) was treated with a 1% solution of trifluoroacetic acid in water (3.495L, 2.5vol). TLC analysis (ethyl acetate; visualisation UV; product R_f 0.35, 0.48 *Z*, *E*) indicated reaction completion after 30 minutes. The pH of the reaction mixture was adjusted to pH 7 with sat. aq. sodium hydrogen carbonate

solution (1.00L, 0.72vol) and ethyl acetate (6.990L, 5vol) charged. The layers were separated, the organic phase washed with sat. aq. sodium hydrogen carbonate solution (2.796L, 2.0vol), the aqueous washes combined and back-extracted with ethyl acetate (2.796L, 2.0vol). The organics were combined, washed with brine (4.794L, 3vol), dried over magnesium sulphate (1.164Kg, 0.75wt), filtered and the filter-cake washed with ethyl acetate (2x 0.699L, 2x 0.5vol). The combined filtrates were concentrated under reduced pressure at 40 to 45°C to give an oily residue which was combined with the residue from a second batch of similar input. Total crude: 2.592Kg. The crude material was dissolved in acetonitrile (2.592L, 1vol), heptanes (26.00L, 10vol) charged and the resultant heated to and maintained at 45 to 55°C for 30 minutes. The lower acetonitrile phase was separated, charged to vigorously stirred *t*-butyl methyl ether (56.00L, 22vol), the mixture cooled to and aged at 0 to 5°C for 1 to 2 hours, filtered and concentrated under reduced pressure at 40 to 45°C to give the title compound as a pale yellow solid (2.037Kg, 93.3%).

Example 3: (3*EZ*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-{5-[(dimethylamino)-methyl]-1,2,4-oxadiazol-3-yl}-3-pyrrolidinone *O*-methyloxime; (3*Z*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-{5-[(dimethylamino)-methyl]-1,2,4-oxadiazol-3-yl}-3-pyrrolidinone *O*-methyloxime; (3*E*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-{5-[(dimethylamino)-methyl]-1,2,4-oxadiazol-3-yl}-3-pyrrolidinone *O*-methyloxime

In this example, step 1, 2, and 3 are the same as in example 2.

Step 4a: Preparation of (2S,4Z)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxy-imino)-2-pyrrolidinecarbonitrile (compound (VIIa) in scheme 7)

A 6L three-necked flask under a nitrogen atmosphere containing (2*S*)-1-(biphenyl-4-ylcarbonyl)-4-(methoxyimino)-pyrrolidine-2-carboxylic acid (151.95 g; 449.39 mmol; 1.00 eq.) in dry THF (2 500.00 ml) was cooled to -20°C prior to adding triethylamine (62.46 ml; 449.39 mmol; 1.00 eq.) (the temperature rose to -15°C) . The solution was stirred for 10 minutes and the temperature was brought to -35°C. Ethyl chloroformate (42.78 ml; 449.39 mmol; 1.00 eq.) was added to the solution over 10 minutes, maintaining the temperature at -35°C. The reaction mixture was stirred for 2h

allowing the temperature to rise up to -20°C. An additional amount of 4 ml of ethyl chloroformate was added drop-wise over 5 minutes and the reaction mixture was stirred at -20°C for 30 minutes. An ammonia saturated THF solution was prepared by bubbling ammonia through 500ml of dry THF for 20 minutes at -60°C under a nitrogen atmosphere in a 2L three necked-flask. The ammonia solution was added to the reaction flask with a dropping funnel maintaining the temperature below -25°C. The solution was allowed to attain room temperature over 3h and the reaction mixture was stirred at overnight. The reaction mixture was cooled to 10°C and additional 250ml of an ammonia saturated THF solution were added drop-wise at -60°C within 10 minutes. Reaction was then stirred allowing temperature to warm to room temperature. Ammonia was directly bubbled in the reaction mixture at 15°C for 10 minutes after stirring for 3h. The reaction mixture was concentrated under vacuum to a volume of 1 L. The resulting slurry was filtered and the remaining residue was washed with 0.1N NaOH. The solid was rinsed with water and dried to give (2S,4Z)-1-([1,1'-biphenyl]-4-yl-carbonyl)-4-(methoxyimino)-2-pyrrolidinecarboxamide (102.10 g; 67.34%). A 3L three-necked flask containing (2S,4Z)-1-([1,1'-biphenyl]-4-yl-carbonyl)-4-(methoxyimino)-2-pyrrolidinecarboxamide (102.10 g; 302.63 mmol; 1.00 eq.) and toluene-4-sulfonyl chloride (86.54 g; 453.94 mmol; 1.50 eq.) in pyridine (1 500.00 ml) was stirred at 80°C overnight until completion. Volatile components were removed under vacuum and the residue was taken up in DCM (1L). The organic phase was washed with HCl 1N (2x 500ml) then with a saturated solution of $NaHCO_3$ (1x500ml). The organic phase was dried over $MgSO_4$, filtered and concentrated to give a black residue (m=178g). This residue was taken up in DCM 350ml and the resulting suspension was filtered to give a cream powder. The filtrate was injected on a chromatographic column (Novasep) (dichloromethane) to be purified. Fractions of interest were combined and concentrated to give a brown residue, which was combined with the previously isolated solid (cream powder). The combined solids were diluted with methyl t-butyl ether (500ml), the suspension was filtered and rinsed with methyl t-butyl ether to give (2S,4Z)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinecarbonitrile (60.00 g; 62.08%).

Step 4b: Preparation of (3*EZ*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}-3-pyrrolidinone *O*-

methyloxime; (3*Z*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}-3-pyrrolidinone *O*-methyloxime; (3*E*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}-3-pyrrolidinone *O*-methyloxime

In a 2L three necked flask containing (2S,4Z)-1-([1,1'-biphenyl]-4-ylcarbonyl)-4-(methoxyimino)-2-pyrrolidinecarbonitrile (59.10 g; 185.06 mmol; 1.00 eq.) and hydroxylamine hydrochloride (15.43 g; 222.07 mmol; 1.20 eq.) in EtOH (1 200.00 ml) at room temperature, triethylamine (30.87 ml; 222.07 mmol; 1.20 eq.) was added drop-wise over 5 minutes. Then the reaction mixture was stirred at 80°C overnight to show completion. The temperature was allowed to cool to room temperature and the EtOH was removed under vacuum. Water (1L) was added and the suspension was filtered off. To remove any by-products, the solid was washed twice with acetonitrile (2x100ml) then with diethyl ether (1x100ml) to give a 75% pure product. After drying under vacuum at room temperature (2S,4Z)-1-(biphenyl-4-carbonyl)-N'-hydroxy-4-(methoxyimino)-pyrrolidine-2-carboximidamide (55.06 g; 84.43%) was obtained.

To a suspension of (2S,4Z)-1-(biphenyl-4-carbonyl)-N'-hydroxy-4-(methoxyimino)-pyrrolidine-2-carboximidamide (11.5 g; 32.63 mmol; 1.00 eq.), 4-dimethylamino-pyridine (4.78 g; 39.16 mmol; 1.20 eq.), N,N-dimethylglycine (= R^7-COOH; 4.04 g; 39.16 mmol; 1.20 eq.) in 1000ml of DCM/DMF(1:1), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (6.88 g; 35.90 mmol; 1.10 eq.) was added. The resulting beige suspension was stirred at room temperature. Stirring was continued overnight. The solvent was removed under reduced pressure, the remaining oily brown residue was dissolved in dichlormethane, washed twice with 5 % citric acid (addition of brine was required to break the emulsion) and twice with sat. $NaHCO_3$, the organic layer was dried over $MgSO_4$ and concentrated under reduced pressure to give 12.45 g of a yellow-brownish solid. Said solid was split into three identical batches (~ 4.15 g), each batch was dissolved in 500 ml of pyridine and the resulting solutions were heated up to ET = 120°C o/n until completion. The batches were combined, the pyridine was removed under vacuum, the remaining residue was dissolved in DCM, washed twice with 5 % citric acid (phase separation was only

possible after addition of brine due to formation of an emulsion), dried over $MgSO_4$ and evaporated under reduced pressure to give 12.9 g of a black oil. The crude product was pre-purified by plug filtration (silica; dichlormethane/MeOH = 95:5) to yield 10.67 g of a brown oil.

Purification of the E/Z product was performed with a column (using conventional silica; EtOAc/cyclohexane = 9:1). The first purification allowed to totally remove all by-products allowing for the isolation of the product as off-white solid (m = 6.73 g). A second purification applying the same conditions delivered pure Z isomer: (3*Z*,5*S*)-1-([1,1'-biphenyl]-4-ylcarbonyl)-5-{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}-3-pyrrolidinone *O*-methyloxime (4.937 g; 36 %).

Claims

1. A method of preparing a compound according to formula (I) :



(I)

wherein

A is a carbonyl group -(C=O)-;

B is either an amido group of formula –(C=O)-NR_3R_4 or an oxadiazole ring of any of the formulae:



(Xa)



(Xb)

R_7 is selected from the group comprising or consisting of hydrogen, sulfonyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, wherein said alkyl, alkenyl, alkynyl chains may be interrupted by a heteroatom selected from N, O or S, aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl, hetero-cycloalkyl, wherein said cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl, heterocycloalkyl, aryl or heteroaryl group, an acyl moiety, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl, C_1-C_6-alkenyl aryl, C_1-C_6-alkenyl heteroaryl, C_1-C_6-alkynyl aryl, C_1-C_6-alkynyl heteroaryl, C_1-C_6-alkyl cycloalkyl, C_1-C_6-alkyl heterocycloalkyl, C_1-C_6-alkenyl cycloalkyl, C_1-C_6-alkenyl heterocycloalkyl, C_1-C_6-alkynyl cycloalkyl, C_1-C_6-alkynyl heterocycloalkyl, alkoxycarbonyl, aminocarbonyl , C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl alkoxy-

carbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl amino, C_1-C_6-alkyl ammonium, C_1-C_6-alkyl sulfonyloxy, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfonylamino, C_1-C_6-alkyl aminosulfonyl, hydroxy, halogen, cyano;

R_1 is H or a C_1-C_6-alkyl;

R_2 is selected from the group comprising or consisting of aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl;

R_3 and R_4 are independently selected from the group comprising or consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, alkoxy, sulfanyl, acyl, alkoxycarbonyl, aminocarbonyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl;

said method comprises the following steps :

Step 1 : transformation of the pyrrolidine of formula (II) into an acyl derivative of formula (IV) using an acylating agent (III) :



(II) (III) (IV)

Step 2 : Oxidation of the acyl derivative (IV), with a oxidizing agent, obtaining a pyrrolidone of formula (V) :

(IV) (V)

Step 3 : Transformation of the pyrrolidone of formula (V) into compound (VII) using a suitable alkoxylamine, aryloxylamine or hydroxylamine of general formula (VI) :



(V) (VI) (VII)

Step 4 : Transformation of the compound (VII) with an amine of general formula (VIII) or an N-hydroxyamidine of general formula (IX) thus yielding compounds (Ia) and (Ib), or transforming compound (VII) first into a nitrile (VIIa), which is then transformed into the hydroxyamidine (VIIb) that is then reacted with a carboxylic acid R^7-COOH to yield compound (Ic). :



(VII) (VIII) (IX) (Ia) (Ib) (VIIa) (VIIb) (Ic)

2. The method according to claim 1, wherein the acyl chloride of step 1 is 1'1-biphenyl-4-carbonyl chloride or 2'-methyl-1'1-biphenyl-4-carbonyl chloride.

3. The method according to claim 1 or 2, wherein the oxidizing agent of Step 2 is pyridine-sulfurtrioxide complex (Py-SO_3) in combination with DMSO.

4. The method according to claim 3, wherein the reaction is performed in presence of triethylamine.

5. The method according to any of claims 1 to 4, wherein the alkoxylamine used in step 3 is O-methylhydroxylamine hydrochloride.

6. The method according to any of claims 1 to 5, wherein R_1 is a methyl group, R_2 is a biphenyl.

7. The method according to any of claims 1 to 6, wherein B is an amido group of the formula $-(C=O)NHR_5$, with R_5 being an C_1-C_6-alkyl aryl group.

8. The method according to claim 3, wherein R_5 is a phenylethyl group which is substituted with an amino or hydroxy group.

9. The method according to any of claims 1 to 7, wherein B is a 1,2,4 oxadiazole substituent



(Xa)

(Xb)

with R_7 being a C_1-C_6-alkyl or a cycloalkyl optionally containing one or 2 hetereroatoms.

Abstract

The present invention is related to a new synthesis for preparing pyrrolidine oximes of general formula (I). The compounds of formula (I) are useful in the treatment and/or prevention of preterm labor, premature birth and dysmenorrhea.



(I)

A is a carbonyl group -(C=O)-;

B is either an amido group of formula –(C=O)-NR_3R_4 or an oxadiazole ring;

R_1 is H or a C_1-C_6-alkyl;

R_2 is selected from the group comprising or consisting of aryl, heteroaryl, saturated or unsaturated 3-8-membered cycloalkyl;

R_3 and R_4 are independently selected from the group comprising or consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, alkoxy, sulfanyl, halogen, cyano, nitro, acyl, alkoxycarbonyl, aminocarbonyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C_1-C_6-alkyl aryl, C_1-C_6-alkyl heteroaryl.